Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT sequential camrelizumab plus trifluridine/tipiracil for MSS/pMMR colorectal cancer liver metastases
ChiCTR2400084157Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and trifluridine + tipiracil in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Started May 2024; status: recruiting.
02
Drugs
camrelizumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR2400084157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084157.